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Abstract
Background: Many neurological diseases are accompanied by an increase in the cerebrospinal fluid (CSF) protein
concentration, which indicates dysfunction of the blood-CSF/blood–brain barrier. However, the significance CSF
protein concentration of patients with cryptococcal meningitis (CM) is not fully understood. The aim of the present
was to determine whether CSF protein concentrations correlated with the responses of patients to treatment with
antifungal drugs.
Methods: We conducted a retrospective study of the analytical data of 623 lumbar punctures of 46 patients with
CM who were treated at West China Hospital. We divided the patients into groups with good or poor responses to
antifungal treatment. We used a generalized linear mixed model (GLMM) to evaluate the significance of the
differences between the two groups.
Results: The baseline CSF protein concentrations of the good antifungal response group (GR-group) (median = 0.97 g/L)
were higher compared with those of the poor antifungal response group (PR-group) (median = 0.72 g/L). Analysis using
the GLMM indicated that the CSF protein concentration of the GR-group decreased at a rate of 1.8 mg/L per day after
antifungal treatment started and was 2.1 mg/L higher compared with that of the PR-group.
Conclusions: Compared with poor responders, we found that the baseline CSF protein concentrations of good
responders were higher and decreased at faster rate after the initiation of antifungal treatment.
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Background
Cryptococcal meningitis (CM) caused by Cryptococcus
neoformans and Cryptococcus gattii [1] is notorious for
prolonged treatment and high mortality [2–4]. There is
an increasing number of cases caused by Cryptococcus
gattii, which infects both immunosuppressed and im-
munocompetent individuals [5]. In contrast, there are
reports of immunocompetent patients infected with C.
neoformans [6–8]. This disease imposes a great burden
worldwide, particularly in sub-Saharan Africa [3].
Lumbar puncture (LP) is advocated for the diagnosis and
management of patients with CM [9, 10]. Analyses of the
cerebral spinal fluid (CSF) of patients with CM patients
provide a wealth of clinical data acquired through the use
of the India ink stain, microbial culture, and biochemical
tests. The CSF protein concentration is important as well,
because increased concentrations are present in patients
with neurological diseases. This condition is referred to as
blood-CSF/blood–brain barrier dysfunction [11]. However,
the clinical implication of differences in CSF protein con-
centrations in patients with CM is not fully understood.
The clinical interpretation of the levels of CSF protein
concentrations is difficult, because the values change
during treatment, and most studies report a single data
point data rather than a time course. In the present
study, we conducted a retrospective analysis of patients
with CM who received antifungal treatment in our hos-
pital and evaluated the clinical implication of the longi-
tudinal data of CSF protein concentrations and the
association with patients’ outcomes.* Correspondence: lv.xiao.ju@hotmail.com
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We analyzed the data for 46 patients who were admitted
to West China Hospital from 2009 to 2014. CM was di-
agnosed according to clinical symptoms and a positive
culture of the CSF or the results of the India ink stain.
Patients with CM were included in this study if they met
all the criteria as follows: 1) monitored for more than
30 days, 2) treated with antifungals for no longer than
7 days before admission, 3) not suspected of intracranial
infection with other pathogens, and 4) CSF data acquired
on a regular basis. All patients were administered antifun-
gal treatment according to ithe guidelines of the Infectious
Diseases Society of America [9]. Typically, patients require
multiple LPs for regular follow-up after discharge. The
Ethics Committee in West China Hospital approved this
retrospective study.
LPs and assay of CSF protein concentration
LPs were routinely performed approximately once each
week for each patient. The CSF samples were immedi-
ately sent to the laboratory and analyzed for crypto-
coccal antigen, cell counts, and biochemical parameters.
India ink staining and fungal cultures were performed as
well. The India ink stain, fungal cultures, biochemical
tests, and cell counts were compulsory and the other
tests were optional. The CSF protein concentration data
for each patient were sorted in chronologically with the
baseline data (before antifungal treatment) listed first for
each patient.
Definitions of patients’ responses to antifungal drugs
We aimed to explore the association between patients’
responses to treatment with antifungal drugs and CSF
protein concentrations. Patients were assigned to the
poor antifungal response group (PR-group) according to
the criteria as follows: persistent positive culture or posi-
tive India ink stain of the CSF 30 days after initiation of
antifungal therapy. The other patients were assigned to
the good antifungal response group (GR-group).
Statistical analysis
A generalized linear mixed model (GLMM) was used for
the statistical analysis. This model is suitable for analyz-
ing repeated measures data [12]. The data acquired
using the GLMM were analyzed using R software [13]
and the nlme [14] and ggplot2 [15] packages. The values
of categorical variables are represented as frequencies,
and the values of continuous variables are presented as
the mean, standard deviation (SD), range, or median
values. The Student t test and the Wilcoxon rank sum test
were used to evaluate the significance of differences be-
tween the values of continuous variables. Spearman’s rank
correlation test was used to test bivariate correlations. The
Fisher’s exact test were used to evaluate the significance of
differences between the values of categorical variables.
Results
There were no significant differences between age, sex, and
underlying diseases of the GR and PR groups (Table 1).
The observation periods ranged from 32 days to 457 days.
Patients received antifungal treatment within several days
after admission. Two patients died while hospitalized.
Clinical treatment of patients with CM employs
amphotericin B (AMB) and flucytosine to decrease the
fungal burden in the central nervous system (CNS) [16].
To achieve a better outcome, most patients receive treat-
ment that includes AMB [17]; however, we found that
the implementation of antifungal strategies varied be-
cause of practical considerations such as costs, side
effects, and availability of drugs (e.g. flucytosine was
temporarily unavailable). The antifungal strategies are
listed in Table 2, and analysis using the Fisher's exact
test did not reveal significant differences between the
groups.
Responses to antifungal treatment
Thirty days after initiating antifungal treatment, the
CSFs of 18 (39.1 %) of 46 good responders were sterile,
and the India ink stains were positive for the other 28
(60.9 %) patients. However, the clinical responses of the
groups did not correspond completely with the CSF data
described below.
CSF protein concentrations
Analysis using the Wilcoxon rank sum test revealed sig-
nificant difference between the median values of baseline
CSF protein concentrations of the groups (P = 0.04)
Table 1 Demographics and underlying diseases of patients
with CM
Variables PR-group (n = 28) GR-group (n = 18) P-value
Age, year
Mean/SD 35.07/12.48 41.00/13.67 0.15
Range (min-max) 16-60 18-67 -
Sex, male 19(67.9 %) 13(72.2 %) 1.00
Diabetes mellitus 2(7.14 %) 2(11.1 %) 0.63
Kidney diseases 1(3.57 %) 0(0.00 %) 1.00
Autoimmune diseases 3(10.7 %) 2(11.1 %) 1.00
HIV positive 2(7.14 %) 2(11.1 %) 0.64
Malignancy 1(3.57 %) 0(0.00 %) 1.00
Hypertension 0(0.00 %) 1(5.56 %) 0.43
Respiratory infection 8(28.6 %) 4(22.2 %) 0.74
Cardiovascular diseases 1(3.57 %) 0(0.00 %) 1.00
HBV positive 4(14.3 %) 1(5.56 %) 0.64
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(Fig. 1). The median value of the CSF protein concentra-
tion of patients in the good response group was 0.97 g/L
and was >0.45 g/L (the upper limit of the normal value)
for 16 patients (88.8 %). In contrast, median value of the
CSF protein concentrations of patients in the poor anti-
fungal response group was 0.72 g/L, and the CSF protein
concentrations were >0.45 g/L for 18 (64.2 %) patients.
Analysis using the GLMM revealed the relationship
between CSF protein concentrations and time (Fig. 2).
Further, the data indicated that the CSF protein concen-
trations of patients in the good antifungal response
group decreased at an average rate of 1.8 mg/L per day
after antifungal therapy started. This value was 2.1 mg/L
higher compared with that of the poor antifungal re-
sponse. The CSF protein concentration of the GR-group
before antifungal treatment was 0.8500 g/L, 0.3221 g/L
higher compared with that of the PR-group (Table 3).
These results indicate that the CSF protein concentra-
tions were higher among the patients in the good anti-
fungal response group before therapy started and that
the concentrations decreased faster compared with
those among patients in the poor antifungal response
group (Fig. 2).
Discussion
We show here that patients in the good antifungal re-
sponse group had higher baseline CSF protein concentra-
tions, which indicates an increased inflammatory response
in the CNS [18]. A plausible hypothesis to explain the data
is that the intensity of the inflammatory response influ-
ences the antifungal response, and the CSF protein con-
centrations simply represent the intensity of inflammatory
responses. Another study of patients with CM found that
those infected with hepatitis B virus (HBV) had lower CSF
white blood cell (WBC) counts and lower percentages of
total protein in the CSF > 0.45 g/L, indicating a lower in-
tensity of immune inflammation compared with patients
with CM who were not infected with HBV who had a
lower survival rate [19]. These findings indicate a correl-
ation between the intensity of inflammatory responses and
clinical outcomes.
A prospective study of patients with CM indicates that
the baseline number of CSF colony-forming units (CFUs)
is a prognostic factor, because patients with a lower num-
ber of CSF CFUs had better clinical outcomes [20]. An-
other study found a negative correlation between protein
concentrations and fungal burdens in the CSF [21]. The






AMB 1(3.57 %) 1(5.56 %) 1.00
AMB+ flucytosine 5(17.9 %) 5(27.8 %) 0.73
AMB+ fluconazole 5(17.9 %) 2(11.1 %) 0.70
AMB+ fluconazole + flucytosine 13(46.2 %) 7(38.9 %) 0.79
AMB+ voriconazole 0(0.00 %) 1(5.56 %) 0.44
Fluconazole 3(10.7 %) 0(0.00 %) 0.29
Fluconazole + flucytosine 0(0.00 %) 2(11.1 %) 0.17
Voriconazole 1(3.57 %) 0(0.00 %) 0.62
Fig. 1 Baseline CSF protein concentrations. The difference between
groups was statistically significant (P = 0.04). *G: GR-group; P: PR-group
Fig. 2 CSF protein concentrations after initiation of antifungal therapy.
*G: GR-group; P: PR-group
Table 3 Parameters of the GLMM estimation
Parameters Estimation SE P-value
Intercept 0.8500 0.0755 0.0000
Time (days) −0.0018 0.0004 0.0000
Groups# −0.3221 0.0847 0.0004
Times (days) by Groups# 0.0021 0.0005 0.0000
#0 = GR-group; 1 = PR-group
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higher baseline CSF protein concentrations reported here
indicate a lower fungal burden, which indicated a better
antifungal response. Others found that a higher WBC cor-
relates with a good clinical response [21, 22] as well as a
positive correlation between WBC count and CSF protein
concentration was found in this study(Spearman’s rank
correlation: R = 0.34, P = 0.00). Because drug concentra-
tions in the CSF may be higher during inflammation of
the CNS compared with those of patients without inflam-
mation [23, 24], an elevated CSF protein concentration
might indicate a higher level of inflammation that in-
creases the transport of AMB to the CNS [24]. The rapid
decrease of the CSF protein concentration in the GR-
group indicates faster attenuation of inflammation, which
led to a more effective antifungal response.
There are differences between the findings of the
present study and those of other reports. For example,
Lu et al., (1999) reported no significant difference in
CSF protein concentrations between treatment failures
and cured or improved groups [22]. However, the value
of a single LB was not sufficient to evaluate the signifi-
cance of changes in CSF protein concentrations during
treatment. The difference may be attributed to the type
of data analysis used compared with that of the present
study. In the present study, we determined the time
course of changes in CSF protein concentrations. Patients
with CM are frequently immunocompromised, for ex-
ample, those with infected with HIV [1]. However, only
four (8.70 %) patients studied here were infected with
HIV, which is lower compared with the rates reported by
others [25]. The multiple polymorphisms in the genes en-
coding mannose-binding lectin and the Fc-gamma recep-
tor 2B (FCGR2B) in the Han population, which is the
largest ethnic group in China, might contribute to the
discrepancies between studies [26]. The mortality rates
(4.34 %) of patients treated at our hospital are lower com-
pared with those of other studies [1]. The lower propor-
tion of HIV-related infections may explain the discrepancy
as well, and observations over eight years reveal that mor-
tality rates are lower for patients with CM who are not
infected with HIV [27].
Conclusions
The present study supports the hypothesis that there is a
correlation between antifungal responses and CSF pro-
tein concentrations. These findings must be confirmed
by prospective studies of larger numbers of patients.
However, we recommend that the treatment of patients
with CM should include detailed analyses of CSF protein
concentrations with focus on their variability.
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